Hereditary angioedema with C1Inh deficiency

This study tracks 40 children aged 2 to 12 with hereditary angioedema (HAE) who are taking lanadelumab to prevent sudden, painful swelling attacks. Researchers will look at medical records to see how long kids stay attack-free and how the drug performs in daily life. No new treat…

This study looked at how a new oral medication (sebetralstat) works in the bodies of 11 teenagers aged 12 to 17 with hereditary angioedema (HAE) types I or II. The goal was to measure drug levels and timing in the blood. All participants were already in a larger HAE trial. The st…

This study looked at the long-term safety of an oral medication called KVD900 for treating swelling attacks in people with hereditary angioedema (HAE) types I or II. The trial enrolled 145 adolescents and adults who had already completed a previous study. Participants took KVD900…

This study tested a drug called Garadacimab in 22 children aged 2 to 11 with hereditary angioedema, a condition that causes sudden, painful swelling. The drug is given as a shot under the skin to prevent attacks. The study looked at safety and how well it works. It has already be…

This study tested the long-term safety and effectiveness of garadacimab, a monthly injection, for preventing attacks of hereditary angioedema (HAE) — a rare condition causing severe swelling. 171 people aged 12 and older who had frequent HAE attacks took part. The goal was to see…

This early trial tested a new drug called navenibart in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received one or two doses of the drug to check its safety and how well it might reduce attacks. The study is …

This study followed 48 people with hereditary angioedema (HAE) in Poland who were taking lanadelumab as part of a national drug program. Researchers tracked how many participants remained attack-free over 24 months, how many attacks still needed rescue treatment, and the severity…

This study tested an oral medication called deucrictibant for quickly treating attacks of hereditary angioedema (HAE), a condition causing sudden, painful swelling. The trial involved 134 adolescents and adults with HAE types 1, 2, or 3. Participants took either the drug or a pla…

This study tested an oral drug called BCX4161 to prevent attacks of hereditary angioedema (HAE), a condition that causes sudden, painful swelling. Over 12 weeks, 110 adults with HAE took either a low dose, high dose, or placebo pill. Researchers tracked how many swelling attacks …

This study tested a drug called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) types I or II, a condition that causes sudden, painful swelling. The goal was to see if the drug is safe and how well it works to relieve attacks. The trial was open-label, m…

This study tested an oral medication called deucrictibant for quickly relieving swelling and pain attacks in people with hereditary angioedema (HAE) types I and II. 74 adults received either one of three doses of the drug or a placebo during an attack. The main goal was to see if…

This completed French survey of 300 hereditary angioedema (HAE) patients and their caregivers aimed to understand the challenges of using on-demand treatments for HAE attacks. Researchers collected data on attack frequency, severity, treatment delays, hospitalizations, and the fi…

This study looked at gene activity in immune cells from 30 people with hereditary angioedema and healthy volunteers. The goal was to see if certain receptors on monocytes are linked to inflammation and blood vessel problems. No treatment was given; the study was purely observatio…

This study followed 88 people with hereditary angioedema (HAE) types I or II who already use icatibant for sudden attacks. Participants filled out diaries for 48 hours after each attack to report symptom changes, severity, and anxiety levels. The goal was to gather real-world inf…